Implications of Medical Low Dose Radiation Exposure (MEDIRAD)

Project Details


MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection (RP) in the medical field and thereby addresses the need to understand and evaluate the health effects of low dose ionising radiation exposure from diagnostic and therapeutic imaging and from off-target effects in radiotherapy (RT).
MEDIRAD will pursue 3 major operational objectives: First, it will improve organ dose estimation and registration to inform clinical practice, optimise doses, set recommendations and provide adequate dosimetry for clinical-epidemiological studies of effects of medical radiation. Second, it aims to evaluate and understand the effects of medical exposures, focusing on the two major endpoints of public health relevance: cardiovascular effects of low to moderate doses of radiation from RT in breast cancer treatment incl. understanding of mechanisms; and long-term effects on cancer risk of low doses from CT in children. Third, it will develop science-based consensus policy recommendations for the effective protection of patients, workers and the general public.
Within the 4-year project a multi-disciplinary consortium will, in close interaction with European medical associations, MELODI and EURADOS (1), develop a tool to determine image quality to maximise optimisation of RP in medical imaging, (2) improve and develop new individual organ/anatomical structure dosimetry from chest CT, I131 administration, fluoroscopy-guided procedures, hybrid imaging, and RT for breast cancer and interlinks with image quality measures, (3) conduct epidemiological studies of consequences of RT and CT, (4) identify potential novel imaging and circulating biomarkers and mechanisms of radiation effects, (5) develop innovative risk models, (6) develop and implement for the first time a European repository of patient dose and imaging data, (7) develop science-based recommendations, and (8) introduce novel approaches to bring together the nuclear and medical sectors.
Effective start/end date1/06/1728/02/22

Collaborative partners

  • EIBIR gemeinnützige GmbH zur Förderung der Erforschung der biomedizinischen Bildgebung (lead)
  • University College Dublin (UCD)
  • Paris V Descartes University
  • University of Bristol
  • Associação para Investigação e Desenvolvimento da Faculdade de Medicina (CCUL)
  • B-Com
  • Otto-von-Guericke Universitat Magdeburg
  • Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
  • Catalan Institute of Oncology
  • Instytut Medycyny Pracy Im. Prof. J.Nofera ( Nofer Institute of Occupational Medicin)
  • French Institute of Health and Medical Research
  • Institut de Radioprotection et de Sûrete Nucléaire (IRSN)
  • Barcelona Institute for Global Health (ISGlobal)
  • Istituto Superiore di Sanità (ISS)
  • Klinikum Rechts der Isar der Technischen Universitaet Muenchen
  • Newcastle University
  • Philipps Marburg Universität
  • The Royal Marsden NHS Foundation Trust
  • Centre d'Etude de l'Energie Nucléaire SCK·CEN
  • University of Coimbra (UC)
  • Ghent University (Universiteit Gent)
  • Universitaetsklinikum wuerzburg - klinikum der bayerischen julius-maximilians-universität
  • Academisch ziekenhuis groningen
  • Stichting Vu-Vumc
  • Panepistimio Kritis (University of Crete)
  • Johannes Gutenberg University of Mainz
  • Università degli Studi di Roma-Sapienza
  • Universitat Politècnica de Catalunya (UPC)
  • Vastra Gotalands Lans Landsting (VGR)
  • Universitat Autònoma de Barcelona (UAB)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.